LRMR · Larimar Therapeutics Inc
United States · RS rating 5 · As of 2026-10-14
| Price | 2.09 USD |
|---|---|
| 1-day change | -3.2% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 3 / 7 / 14 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 13 / 16 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | -19.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +64.9% |
| Market cap (USD) | $467.5M |